Study cohort
Available baseline plasma samples from the placebo arm of the IPF randomized control trial CAPACITY-006 (NCT00287729) were used for LPA (n = 102) and global lipidomic (n = 99) measurements. The design of the clinical trial has been described (The study was approved by independent ethics committees and institutional review boards at each institution and by InterMune Inc or designees and conducted according to the standards of the Declaration of Helsinki. Written informed consent was obtained from participants prior to biomarker analysis.